Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more
Alembic Pharmaceuticals Limited (APLLTD) - Total Liabilities
Latest total liabilities as of September 2025: ₹30.81 Billion INR
Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) has total liabilities worth ₹30.81 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alembic Pharmaceuticals Limited - Total Liabilities Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alembic Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Alembic Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Accolade, Inc.
NASDAQ:ACCD
|
USA | $334.45 Million |
|
Bravura Solutions Limited
PINK:BVSFF
|
USA | $86.26 Million |
|
IMMOFINANZ AG
VI:IIA
|
Austria | €5.19 Billion |
|
SFTCF
PINK:SFTCF
|
USA | $636.55 Million |
|
Qingdao Doublestar Co Ltd
SHE:000599
|
China | CN¥7.76 Billion |
|
Guangdong LingXiao Pump Industry Co Ltd
SHE:002884
|
China | CN¥170.06 Million |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥65.72 Million |
|
MilDef Group AB
ST:MILDEF
|
Sweden | Skr1.39 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Alembic Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alembic Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alembic Pharmaceuticals Limited (2011–2025)
The table below shows the annual total liabilities of Alembic Pharmaceuticals Limited from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹25.83 Billion | +58.75% |
| 2024-03-31 | ₹16.27 Billion | -10.21% |
| 2023-03-31 | ₹18.12 Billion | -3.83% |
| 2022-03-31 | ₹18.84 Billion | +14.77% |
| 2021-03-31 | ₹16.42 Billion | -41.33% |
| 2020-03-31 | ₹27.99 Billion | +35.87% |
| 2019-03-31 | ₹20.60 Billion | +19.71% |
| 2018-03-31 | ₹17.21 Billion | +119.06% |
| 2017-03-31 | ₹7.85 Billion | -8.54% |
| 2016-03-31 | ₹8.59 Billion | +13.52% |
| 2015-03-31 | ₹7.57 Billion | +39.52% |
| 2014-03-31 | ₹5.42 Billion | -0.49% |
| 2013-03-31 | ₹5.45 Billion | -17.05% |
| 2012-03-31 | ₹6.57 Billion | +19.79% |
| 2011-03-31 | ₹5.48 Billion | -- |